Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

APOE polymorphism in ATTR amyloidosis patients treated with lipid nanoparticle siRNA.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis - 1 Mar 2020

Niemietz Christoph, Nadzemova Oksana, Zibert Andree, Schmidt Hartmut H-J

Abstract excerpt

The novel class of compounds represented by lipid nanoparticle (LNP)-encapsulated siRNA formulations has an enormous potential to target disease, notably of the liver. Endocytosis of LNPs is believed to be mediated by APOE, an important serum protein of lipoprotein homeostasis. APOE polymorphisms affect binding to hepatic receptors and have been associated with development of specific disease. Here, the role of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloid Neuropathies, Familial
Share to Apolipoproteins E

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Knockdown Techniques

Share to Gene Silencing

Share to Hep G2 Cells

Share to Nanoparticles

Share to Prealbumin

Share to RNA, Small Interfering

Source

Identifiers

PMID: 31648569
DOI: 10.1080/13506129.2019.1681392

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

APOE polymorphism in ATTR amyloidosis patients treated with lipid nanoparticle siRNA.PMID 31648569Read ↗

Practical Guidance for the Use of Patisiran in the Management of Polyneuropathy in Hereditary Transthyretin-Mediated AmyloidosisSemantic proximity Read ↗

Update on the clinical utility of an RNA interference-based treatment: focus on PatisiranSemantic proximity Read ↗

Population Pharmacokinetic-Pharmacodynamic Model of Serum Transthyretin Following Patisiran Administration.Semantic proximity Read ↗

Hereditary transthyretin amyloidosis in the era of RNA interference, antisense oligonucleotide, and CRISPR-Cas9 treatmentsSemantic proximity Read ↗

Treating hereditary transthyretin amyloidosis: Present & future challenges.Semantic proximity Read ↗

Patisiran, an RNAi Therapeutic for the Treatment of Hereditary Transthyretin-Mediated AmyloidosisSemantic proximity Read ↗

Safety and Efficacy of RNAi Therapy for Transthyretin AmyloidosisSemantic proximity Read ↗

Modulation of <i>TTR</i> Gene Expression in the Eye using Modified Duplex RNAsSemantic proximity Read ↗

The Extent to Which Lipid Nanoparticles Require Apolipoprotein E and Low-Density Lipoprotein Receptor for Delivery Changes with Ionizable Lipid StructureSemantic proximity Read ↗

Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis.Semantic proximity Read ↗

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin AmyloidosisSemantic proximity Read ↗

Extrahepatic, cell-specific delivery of LNPs through competitive inhibition of ApoE-mediated uptakeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.